| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| CH.1.1.22 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBB.1.36 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBB.1.37 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBB.2.10 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BQ.1.21 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BN.3 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BN.1.8 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.277 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AY.28 (Delta) | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.272 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.371 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AA.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.353 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -15625.1 | US |
| B.1.407 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AA.4 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.160.13 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.47 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.182 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.218 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBB.1.12.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| A.11 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AY.22 (Delta) | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.128 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.36.33 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.405 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.296 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.412 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AC.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| C.27 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.421 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.364 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.82 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.177.61 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.177.47 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.38 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.251 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| A.2.3 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.144 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.288 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.249 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.378 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.97 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.9 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.439 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.408 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.256 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| Q.7 (Alpha) | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.460 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.262 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| EG.9 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -18526.8 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |